At some point, “unprecedented disruption” stops being a useful descriptor. What Resilinc’s 2025 data shows is something more specific: more events, more overlap, and faster downstream impact.
Resilinc’s 2025 Annual Supply Chain Report tracked a 38% year-over-year increase in disruption alerts, and that number doesn’t represent one bad season or a single crisis. It’s a pattern. For pharmaceutical supply chains, where compliance failures and sourcing gaps can directly affect patients, that distinction matters.
Disruption doesn’t arrive in neat, isolated events anymore
In 2025, problems stacked. Natural disasters hit while suppliers were already under financial stress. Regulatory enforcement tightened as logistics networks were still absorbing trade shifts. According to Resilinc’s EventWatchAI data, naturally caused events rose 44% year over year. Labor disruption, the top reported risk category, generated more than 2,300 alerts. Bankruptcy notifications climbed 20%, and profit warnings jumped 50%.
For pharma manufacturers, the compounding effect is what’s dangerous. A weather event affecting a sub-tier API supplier doesn’t stay a sourcing problem for long. It becomes a quality issue, a regulatory issue, and potentially a patient access issue within days.
Compliance now requires proof, not just documentation
Enforcement activity was a steady signal throughout 2025: warning letters, inspections, and fines. What’s shifting is what regulators want to see. Saying you’ve assessed supplier risk isn’t sufficient. You have to demonstrate actual visibility: where materials come from, how they move, what your exposure is if something fails two or three tiers upstream.
That means deeper mapping and continuous monitoring. Annual audits don’t cut it when disruptions move faster than audit cycles.
Supplier financial health is an operational risk
Pharma organizations are good at tracking quality systems. Financial distress is harder to watch and easier to underweight, but in 2025, it proved to be a leading indicator of operational problems. Restructuring, leadership turnover, and cash pressure can quietly erode production capacity and compliance investment, especially in specialty manufacturing environments like sterile injectables or limited-source APIs.
The earlier you pick up on financial stress signals, the more options you have.
Climate exposure is already priced into your supply chain whether you’ve modeled it or not
Extreme weather events climbed sharply in 2025, and it’s not hard to see why pharma feels it acutely. API manufacturing concentrations in South and Southeast Asia, Puerto Rico’s role in sterile injectables, key logistics corridors in flood-prone regions — the industry’s geography creates real exposure. Floods, heat events, and infrastructure failures don’t stay contained. They ripple into utilities, facility uptime, and cold chain integrity. If you haven’t modeled what a major weather event means for your specific network, 2026 is a good time to start.
Three things worth prioritizing now
The organizations that handled 2025 disruptions well shared some common habits:
- they knew their supply chains past Tier 1
- they connected disruption signals to product and revenue impact
- and they had response plans ready before they needed them.
Going into 2026, that translates to a short list. Close the sub-tier visibility gap. If you don’t know where critical inputs originate, you’re exposed regardless of the threat type. Treat compliance signals and operational risk as part of the same workflow rather than separate programs. And build response playbooks now, when there’s time to think, rather than during an active disruption.
For a deeper look at what drove disruption in 2025 and what it signals for the year ahead, Resilinc’s 2025 Annual Supply Chain Report is worth reading before your next planning cycle.
Resilience isn’t about preventing disruption. It’s about how fast you can move from signal to decision. In pharma, that speed has a direct line to patient trust, which is ultimately the metric everything else is serving.
